When diffuse large B-cell lymphoma returns after initial treatment, patients face a challenging journey that requires new therapeutic approaches and renewed strength. Understanding the available treatment options, from advanced stem cell transplants to innovative immunotherapies, helps patients and their families navigate this difficult phase with greater confidence and clarity.

When Lymphoma Comes Back: Understanding the Path Forward

When diffuse large B-cell lymphoma reappears after a period where the disease seemed to be gone, or when it doesn’t respond well to the first round of treatment, patients enter what doctors call the relapsed or refractory phase. The term “relapsed” describes lymphoma that comes back after someone has been in remission, which means there were no visible signs of cancer in the body. “Refractory” refers to lymphoma that doesn’t respond to treatment or when the response doesn’t last very long.^[2]

Understanding that lymphoma has returned or isn’t responding creates enormous emotional and physical challenges. The reality is that around 40 percent of people with diffuse large B-cell lymphoma will experience either refractory disease or relapse after their first line of treatment. About 15 to 20 percent have refractory disease, while 20 to 30 percent experience relapse.^[5] For many people, about one-third who achieve complete remission after the standard first treatment will see their lymphoma return within two years.^[4]

The goal of treating recurrent diffuse large B-cell lymphoma is to bring the cancer back under control, relieve symptoms, and improve quality of life. Treatment choices depend on many factors, including what treatments the person has already received, how long they were in remission, their overall health, and their personal preferences. Some patients may still achieve long-term remission or even cure with appropriate treatment, while others focus on controlling the disease and maintaining the best possible quality of life.^[5]

Medical teams recommend repeating a biopsy—taking a small tissue sample for examination—before starting second-line treatment. This helps confirm that the lymphoma has truly returned and rules out other conditions that might show up on scans but aren’t cancer, such as infections or other diseases. Sometimes imaging tests can give false signals, so having tissue confirmation guides doctors toward the most appropriate treatment plan.^[7]

Standard Treatment Approaches for Recurrent Disease

For patients whose lymphoma has returned or hasn’t responded to initial therapy, several established treatment pathways exist. These approaches have been used for years and form the foundation of care, though they work better for some people than others.

Combination Chemotherapy Regimens

When diffuse large B-cell lymphoma comes back, doctors often turn to different combinations of chemotherapy drugs than those used initially. These are called second-line regimens, and they aim to attack the cancer cells using different mechanisms than the first treatment. Several combination chemotherapy approaches are available for patients with relapsed or refractory disease.^[2]

One commonly used regimen combines ifosfamide, carboplatin, and etoposide, known by the abbreviation ICE. Another option pairs dexamethasone, cisplatin, and cytarabine, called DHAP. Some patients receive gemcitabine-based therapy, which uses this specific drug as the main component along with other medications. These combinations work by damaging cancer cell DNA or interfering with cell division, preventing lymphoma cells from multiplying.^[2]

The medication bendamustine, sold under the brand name Treanda, is sometimes combined with rituximab, a drug called Rituxan that targets a protein called CD20 on the surface of lymphoma cells. Another pairing uses lenalidomide (Revlimid) plus rituximab. These regimens combine traditional chemotherapy with targeted drugs that help the immune system recognize and attack cancer cells more effectively.^[2]

The duration of these chemotherapy regimens varies based on how well someone responds and what side effects they experience. Typically, patients receive several cycles of treatment, with each cycle lasting a few weeks. Between cycles, the body gets time to recover from the effects of the drugs. Doctors monitor response through imaging scans and blood tests to determine whether to continue, modify, or change the treatment approach.

Side Effects of Second-Line Chemotherapy

Second-line chemotherapy regimens often cause stronger side effects than initial treatment because the drugs are more intensive and the body may still be recovering from previous therapy. Common side effects include severe fatigue, where everyday activities become exhausting. Many patients experience nausea and vomiting, though medications can help control these symptoms. Hair loss often occurs, and the digestive system may be affected, causing diarrhea or constipation.

One particularly important side effect is the impact on blood cell production. Chemotherapy reduces the number of white blood cells, which fight infection, making patients much more vulnerable to bacterial, viral, and fungal infections. Red blood cell counts drop, causing anemia that leads to weakness and breathlessness. Platelet levels decrease, raising the risk of bleeding and bruising. Some patients need blood transfusions or medications that stimulate blood cell production to manage these effects.

Certain chemotherapy drugs can affect specific organs. Some may damage the kidneys, requiring careful monitoring of kidney function and plenty of fluids. Others can harm the heart muscle or affect the nervous system, causing numbness, tingling, or pain in the hands and feet. Mouth sores are common and can make eating and drinking painful. Many people also experience changes in taste and appetite.

Stem Cell Transplantation

For many patients with relapsed or refractory diffuse large B-cell lymphoma, high-dose chemotherapy followed by stem cell transplantation offers the possibility of long-term disease control. This intensive approach uses much higher doses of chemotherapy than standard regimens, powerful enough to wipe out cancer cells but also to destroy the bone marrow, which produces blood cells. The transplanted stem cells help rebuild the bone marrow after the high-dose treatment.^[2]

The majority of patients undergoing stem cell transplantation receive an autologous transplant, which means they receive their own stem cells that were collected and frozen before the high-dose chemotherapy. Before the procedure, doctors give medications that push stem cells from the bone marrow into the bloodstream, where they’re collected through a process similar to blood donation. After high-dose chemotherapy destroys the bone marrow, these stored stem cells are returned to the patient’s body through an intravenous line, where they travel to the bone marrow and begin producing new blood cells.^[2]

Occasionally, patients undergo an allogeneic transplant, receiving stem cells from a donor whose tissue type closely matches theirs. This might be a family member or an unrelated donor found through a registry. Allogeneic transplants carry additional risks because the donor’s immune cells may attack the patient’s body, causing a condition called graft-versus-host disease. However, these donor immune cells may also help fight any remaining lymphoma cells.^[2]

The stem cell transplant process is physically and emotionally demanding. The high-dose chemotherapy causes severe side effects, and patients typically spend several weeks in the hospital in isolation to protect them from infections while their immune system rebuilds. Recovery takes months, during which time patients remain vulnerable to infections and must take numerous precautions. Despite these challenges, autologous stem cell transplantation can offer the best chance for long-term remission in appropriate candidates.

New Approved Treatment Options for Relapsed Disease

In recent years, several innovative therapies have been approved specifically for treating relapsed or refractory diffuse large B-cell lymphoma. These newer options provide more effective alternatives than conventional chemotherapy alone and often have manageable safety profiles. They represent major advances in how doctors approach recurrent disease.^[5]

Targeted Antibody Therapies

Several medications that combine antibodies with chemotherapy drugs, called antibody-drug conjugates, have shown promise in treating recurrent lymphoma. Polatuzumab vedotin-piiq, sold as Polivy, is one such therapy approved for use in combination with bendamustine and rituximab. This medication consists of an antibody that finds and attaches to CD79b, a protein found on the surface of B cells, linked to a chemotherapy drug. When the antibody binds to lymphoma cells, it delivers the chemotherapy directly into the cancer cell, killing it from the inside. This targeted approach means the chemotherapy affects cancer cells more than healthy cells.^[2]

Another approved medication is tafasitamab-cxix (Monjuvi), which targets the CD19 protein on B cells. This drug is used in combination with lenalidomide for patients who aren’t candidates for stem cell transplantation. Tafasitamab works by attaching to lymphoma cells and triggering the immune system to destroy them. It also directly blocks signals that cancer cells need to survive and grow.^[2]

Selinexor (Xpovio) represents a different type of targeted therapy called a selective inhibitor of nuclear export. Cancer cells move important proteins out of the cell nucleus to survive. Selinexor blocks this movement, trapping proteins inside the nucleus where they trigger the cancer cell’s self-destruction. This medication is available for patients whose lymphoma has returned after at least two previous treatments.^[2]

Bispecific Antibodies

Two recently approved medications called bispecific antibodies represent an exciting new approach to treating relapsed lymphoma. Epcoritamab-bysp (Epkinly) and glofitamab-gxbm (Columvi) are designed to work like bridges, connecting cancer cells with immune system T cells. These drugs have two binding sites: one attaches to CD20 protein on lymphoma cells, and the other attaches to CD3 protein on T cells. By bringing these cells together, the bispecific antibodies activate the T cells to attack and destroy the lymphoma cells.^[2]

These medications are given through injections or infusions on specific schedules. Early results have shown they can produce responses in patients whose lymphoma didn’t respond to other treatments. Side effects can include reactions during infusion, such as fever, chills, or low blood pressure. Some patients experience a condition called cytokine release syndrome, where activated immune cells release large amounts of signaling molecules that cause inflammation throughout the body. This usually occurs with the first few doses and can be managed with medications and monitoring.

Checkpoint Inhibitors for Specific Subtypes

For patients with a specific subtype of diffuse large B-cell lymphoma called primary mediastinal large B-cell lymphoma, which starts in the chest area, an additional treatment option exists. Pembrolizumab (Keytruda) is a type of drug called a checkpoint inhibitor that works by releasing the brakes on the immune system. Cancer cells often use checkpoint proteins to hide from immune attack. Pembrolizumab blocks one of these checkpoints called PD-1, allowing immune cells to recognize and attack lymphoma cells.^[2]

This medication is given through intravenous infusion every few weeks. Side effects differ from traditional chemotherapy because they result from an overactive immune system rather than direct cell damage. Patients may experience fatigue, skin rashes, or diarrhea. More serious side effects can occur if the activated immune system attacks healthy organs, causing inflammation of the lungs, intestines, liver, or hormone-producing glands. Doctors monitor carefully for these immune-related side effects.

Breakthrough Immunotherapy: CAR T-Cell Therapy

One of the most significant advances in treating relapsed or refractory diffuse large B-cell lymphoma is chimeric antigen receptor T-cell therapy, usually called CAR T-cell therapy. This revolutionary approach has become the new standard treatment for patients with refractory disease or lymphoma that returns quickly after initial treatment. Major clinical trials called ZUMA-7 and TRANSFORM showed that CAR T-cell therapy produced better results than conventional treatment approaches, establishing it as a preferred option for eligible patients.^[5]

CAR T-cell therapy works by genetically modifying a patient’s own immune cells to recognize and attack lymphoma. The process begins with leukapheresis, a procedure where blood is removed from the patient and passed through a machine that separates out T cells, a type of white blood cell that fights infection. The remaining blood is returned to the patient. These collected T cells are sent to a specialized laboratory where scientists insert new genetic instructions that program them to recognize and attack cells carrying the CD19 protein found on B-cell lymphomas.^[2]

The modified T cells, now armed with chimeric antigen receptors on their surface, are multiplied in the laboratory until there are millions of them. This manufacturing process typically takes several weeks. During this waiting period, patients might receive bridging chemotherapy to keep the lymphoma under control. When the CAR T cells are ready, they’re returned to the patient through intravenous infusion. Once in the body, these reprogrammed cells multiply further and begin hunting down and destroying lymphoma cells throughout the body.

Three CAR T-cell therapies have received approval for treating relapsed or refractory diffuse large B-cell lymphoma: axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel or liso-cel (Breyanzi), and tisagenlecleucel (Kymriah). Each product uses slightly different manufacturing approaches and CAR designs, but all target the CD19 protein on lymphoma cells. Doctors choose among these options based on factors like manufacturing time, side effect profiles, and availability.^[2]

Managing CAR T-Cell Therapy Side Effects

While CAR T-cell therapy can produce dramatic responses, it also carries unique and potentially serious side effects that require specialized medical expertise. The most common serious side effect is cytokine release syndrome, which occurs when the activated CAR T cells release large amounts of inflammatory molecules called cytokines. This typically happens within the first week after infusion as the CAR T cells encounter and destroy lymphoma cells.

Cytokine release syndrome causes fever, often very high, along with flu-like symptoms such as chills, fatigue, muscle and joint pain, nausea, and loss of appetite. In more severe cases, it can cause low blood pressure requiring medications to maintain circulation, difficulty breathing that may need oxygen support, and organ dysfunction affecting the heart, kidneys, or liver. Doctors treat cytokine release syndrome with a medication called tocilizumab that blocks one of the main inflammatory cytokines, along with steroids for more severe cases.

Another serious side effect is immune effector cell-associated neurotoxicity syndrome, often called ICANS, which affects the nervous system. Symptoms range from confusion, difficulty speaking, trouble writing, and tremors to more severe problems like seizures or decreased consciousness. This typically occurs in the first few weeks after infusion. Like cytokine release syndrome, ICANS is treated with steroids and supportive care. Most patients recover completely, though recovery may take weeks.

Because of these potential complications, patients receiving CAR T-cell therapy must stay close to the treatment center for at least the first month after infusion. Many centers require patients to remain within a certain distance, sometimes staying in nearby housing. Patients need a caregiver with them at all times during this period. The treatment center must have specialized expertise in managing these side effects and access to intensive care facilities if needed.

Clinical Trials and Experimental Approaches

For patients whose lymphoma has returned despite multiple treatments, or for those seeking the most cutting-edge options, clinical trials offer access to experimental therapies not yet available outside research settings. These studies test new drugs, new combinations of existing drugs, or entirely new treatment approaches to determine if they work better than current options.

Researchers are studying many different strategies to improve outcomes for relapsed or refractory diffuse large B-cell lymphoma. Some trials test whether using newer treatments earlier in the disease course, rather than waiting until several treatments have failed, might produce better results. Other studies examine whether combining different types of therapy, such as pairing targeted drugs with immunotherapy, can enhance effectiveness while managing side effects.

Clinical trials proceed through distinct phases, each designed to answer specific questions. Phase I trials primarily focus on safety, determining the right dose of a new treatment and identifying what side effects occur. These studies usually involve small numbers of patients. Phase II trials evaluate whether the treatment actually works against the cancer, measuring how many patients respond and how long responses last. These trials involve more participants. Phase III trials compare the new treatment directly against the current standard treatment to determine if the new approach is better, using large numbers of patients at multiple medical centers.

Participation in clinical trials contributes to advancing medical knowledge that will help future patients, even if the experimental treatment doesn’t work for every individual participant. Patients in trials receive extremely close monitoring and care from specialized medical teams. They often get access to promising new treatments years before they become widely available. However, experimental treatments may have unknown side effects, and there’s no guarantee they will work better than standard options.

Patients interested in clinical trials should discuss this option with their oncology team, who can help identify appropriate studies based on the patient’s specific situation. Organizations dedicated to lymphoma research and advocacy maintain databases of ongoing clinical trials, making it easier for patients to find studies that might be suitable. Eligibility for trials depends on many factors, including the patient’s disease characteristics, previous treatments, overall health, and sometimes geographic location.

Most common treatment methods

• Combination chemotherapy regimens
  • ICE regimen combining ifosfamide, carboplatin, and etoposide for attacking lymphoma through multiple mechanisms
  • DHAP regimen using dexamethasone, cisplatin, and cytarabine to interfere with cancer cell growth and division
  • Gemcitabine-based therapy utilizing this drug as the main component with other medications
  • Bendamustine plus rituximab pairing traditional chemotherapy with CD20-targeted antibody therapy
  • Lenalidomide plus rituximab combining immunomodulatory drug with targeted antibody
• Stem cell transplantation
  • Autologous transplant using patient’s own stem cells collected before high-dose chemotherapy
  • Allogeneic transplant using donor stem cells from matched family member or registry donor
  • High-dose chemotherapy followed by stem cell rescue to rebuild bone marrow
• Targeted antibody therapies
  • Polatuzumab vedotin-piiq (Polivy) delivering chemotherapy directly to CD79b-positive lymphoma cells
  • Tafasitamab-cxix (Monjuvi) targeting CD19 protein and activating immune destruction of cancer cells
  • Selinexor (Xpovio) blocking nuclear export to trigger cancer cell self-destruction
  • Epcoritamab-bysp (Epkinly) connecting lymphoma cells to immune T cells for targeted killing
  • Glofitamab-gxbm (Columvi) bridging CD20-positive cancer cells with CD3-positive T cells
• CAR T-cell immunotherapy
  • Axicabtagene ciloleucel (Yescarta) using genetically modified T cells targeting CD19
  • Lisocabtagene maraleucel (Breyanzi) employing reprogrammed immune cells to attack lymphoma
  • Tisagenlecleucel (Kymriah) harnessing patient’s own T cells engineered to recognize cancer
• Checkpoint inhibitor therapy
  • Pembrolizumab (Keytruda) for primary mediastinal B-cell lymphoma subtype, releasing immune system brakes to enable cancer recognition and attack